Breaking News Instant updates and real-time market news.

2020-05-01 11:13:09 AEM Agnico Eagle $59.08 / +0.35 (+0.60%) 11:13 05/01/20 05/01 11:13 05/01/20 11:13	Agnico Eagle price target raised to C$60 from C$54 at BMO Capital BMO Capital analyst Jackie Przybylowski raised the firm's price target on Agnico Eagle to C$60 from C$54 and keeps an Outperform rating on the shares.	01 May
AEM Agnico Eagle $59.08 / +0.35 (+0.60%) 05/01/20 CIBC CIBC backs Outperformer on Agnico Eagle after 'solid' Q1 results 05/01/20 RBC Capital Agnico Eagle's Q1 results mixed relative to expectations, says RBC Capital 03/24/20 TD Securities Agnico Eagle upgraded to Buy from Hold at TD Securities 03/02/20 Canaccord Agnico Eagle upgraded to Buy from Hold at Canaccord

2020-05-01 11:13:09

AEM

Agnico Eagle

$59.08 / +0.35 (+0.60%)

11:13

05/01/20

05/01

11:13

05/01/20

11:13

Agnico Eagle price target raised to C$60 from C$54 at BMO Capital

BMO Capital analyst Jackie Przybylowski raised the firm's price target on Agnico Eagle to C$60 from C$54 and keeps an Outperform rating on the shares.

01
May

AEM Agnico Eagle

$59.08 / +0.35 (+0.60%)

05/01/20 CIBC: CIBC backs Outperformer on Agnico Eagle after 'solid' Q1 results

05/01/20 RBC Capital: Agnico Eagle's Q1 results mixed relative to expectations, says RBC Capital

03/24/20 TD Securities: Agnico Eagle upgraded to Buy from Hold at TD Securities

03/02/20 Canaccord: Agnico Eagle upgraded to Buy from Hold at Canaccord

TODAY'S FREE FLY STORIES

Hot Stocks	Adaptive says Genentech suspends development of shared antigen target candidate » 06:53 03/03/21 03/03 06:53 03/03/21 06:53 ADPT Adaptive Biotechnologies $53.11 / -4.75 (-8.21%) , RHHBY Roche $0.00 / + (+0.00%) In a regulatory filing… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events ADPT RHHBY ADPT Adaptive Biotechnologies $53.11 / -4.75 (-8.21%) 02/23/21 Adaptive Biotechnologies expands collaboration with LabCorp 02/23/21 Adaptive Biotechnologies launches T-Detect COVID test 01/11/21 Adaptive in pact with AstraZeneca to investigate use of immunoSEQ T-MAP 12/06/20 Adaptive announces new data demonstrating impact of clonoSEQ Assay RHHBY Roche $0.00 / + (+0.00%) 02/26/21 Regeneron announces CHMP recommendation for COVID-19 antibody cocktail 02/24/21 Prothena announces presentation of new preclinical PRX005 data 02/19/21 Atea Pharmaceuticals announces Chugai in-license of AT-527 from Roche 02/12/21 Genentech announces results from four Phase III studies of faricimab ADPT RHHBY ADPT Adaptive Biotechnologies $53.11 / -4.75 (-8.21%) 01/19/21 BTIG Adaptive Biotechnologies price target raised to $74 from $66 at BTIG 12/17/20 BTIG BTIG positive on select healthcare diagnostic/tools names as '2021 Top Picks' 11/12/20 BTIG Adaptive Biotechnologies price target raised to $63 from $60 at BTIG 11/11/20 JPMorgan Adaptive Biotechnologies price target raised to $60 from $50 at JPMorgan RHHBY Roche $0.00 / + (+0.00%) 02/25/21 Berenberg Roche price target lowered to CHF 320 from CHF 325 at Berenberg 02/24/21 Morgan Stanley Roche price target lowered to CHF 345 from CHF 365 at Morgan Stanley 02/23/21 BofA BofA adds Heineken and IAG, removes Roche and Sanofi from Europe 1 list 02/17/21 UBS UBS downgrades Roche to Neutral on risk to 2022 estimates ADPT RHHBY ADPT Adaptive Biotechnologies $53.11 / -4.75 (-8.21%) 02/24/21 Adaptive Biotechnologies reports Q4 EPS (33c), consensus (29c) 11/10/20 Adaptive Biotechnologies reports Q3 EPS (27c), consensus (28c) RHHBY Roche $0.00 / + (+0.00%) 02/04/21 Roche reports 2020 core EPS CHF 19.16 vs. CHF 20.16 last year 10/27/20 Oncolytics announces new GI cancer study using 10/15/20 Roche confirms outlook for 2020 based on assessment of COVID-19 10/15/20 Roche reports 9 months group sales CHF43.98B vs. CHF46.07B last year 16 Jul RHHBY RHHBY Roche $0.00 / + (+0.00%) 02/11/21 Roche arthritis drug reduced Covid deaths in study, Reuters reports 12/23/20 Judge rules against White House drug pricing rule, Reuters says 11/23/20 EU seeks easier access to generic medicines, Reuters says 11/20/20 Trump to release new rules aimed at lowering drug prices, WSJ reports ADPT RHHBY ADPT Adaptive Biotechnologies $53.11 / -4.75 (-8.21%) 02/16/21 Fly Insider: Power REIT, Amphastar among week's notable insider trades 02/01/21 Fly Insider:Allied Esports,Applied Optoelectronics among notable insider trades 01/19/21 Fly Insider: REV Group, Neurocrine Bio among week's notable insider trades 12/14/20 Fly Insider: Molecular Templates, AMD among notable insider trades RHHBY Roche $0.00 / + (+0.00%) 12/26/20 Week in review: How Trump's policies moved stocks 11/30/20 Fly Intel: Wall Street's top stories for Monday 11/30/20 Fly Intel: Wall Street's top stories at midday 11/21/20 Week in review: How Trump's policies moved stocks 03/25/21 Roche - RHHBY
Initiation	Natixis resumed with a Buy at Citi » 06:51 03/03/21 03/03 06:51 03/03/21 06:51 NTXFY Natixis $0.00 / + (+0.00%) Citi analyst Azzurra… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research NTXFY Natixis $0.00 / + (+0.00%) 02/10/21 BPCE intends to file tender offer for remaining Natixis shares at EUR 4 NTXFY Natixis $0.00 / + (+0.00%) 02/10/21 RBC Capital Natixis downgraded to Sector Perform from Outperform at RBC Capital 02/10/21 Societe Generale Natixis upgraded to Hold from Sell at Societe Generale 01/27/21 Societe Generale Natixis downgraded to Sell from Hold at Societe Generale 01/07/21 Credit Suisse Natixis downgraded to Underperform from Neutral at Credit Suisse
Hot Stocks	Eli Lilly, Incyte announce BRAVE-AA2 study met primary endpoint » 06:51 03/03/21 03/03 06:51 03/03/21 06:51 LLY Eli Lilly $204.13 / -2.26 (-1.10%) , INCY Incyte $78.57 / -1.12 (-1.41%) Eli Lilly (LLY) and… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options LLY INCY LLY Eli Lilly $204.13 / -2.26 (-1.10%) 02/26/21 Eli Lilly awarded $210M Army contract for 100,000 doses of antibody therapeutic 02/26/21 Eli Lilly awarded $2.52B Army contract for LY-CoV555, LY-CoV016 02/26/21 Eli Lilly: Additional doses of neutralizing antibody therapy purchased by U.S. 02/25/21 Eli Lilly, Welldoc announce agreement to create insulin management solution INCY Incyte $78.57 / -1.12 (-1.41%) 02/26/21 Incyte announces EMA validation of retifanlimab MAA 02/22/21 Incyte announces FDA acceptance, priority review for ruxolitinib sNDA 02/19/21 Incyte announces acceptance, priority review for ruxolitinib cream NDA 02/09/21 Incyte sees FY21 Jakafi revenue $2.13B-$2.2B LLY INCY LLY Eli Lilly $204.13 / -2.26 (-1.10%) 03/02/21 JPMorgan Eli Lilly risk/reward favorable into Alzheimer's data, says JPMorgan 02/18/21 H.C. Wainwright Rigel Pharmaceuticals price target raised to $11 from $8 at H.C. Wainwright 02/18/21 Piper Sandler Rigel share setup 'distinctly positive' after Lilly deal, says Piper Sandler 02/12/21 Cowen Eli Lilly price target raised to $235 from $195 at Cowen INCY Incyte $78.57 / -1.12 (-1.41%) 02/10/21 SVB Leerink Incyte downgraded to Market Perform from Outperform at SVB Leerink 01/07/21 Truist Incyte initiated with a Buy at Truist 01/07/21 Truist Incyte initiated with a Buy at Truist 01/04/21 Guggenheim Incyte upgraded to Buy from Neutral at Guggenheim LLY INCY LLY Eli Lilly $204.13 / -2.26 (-1.10%) 01/29/21 Eli Lilly backs FY21 EPS view $7.75-$8.40, consensus $8.20 01/29/21 Eli Lilly reports Q4 EPS $2.75, consensus $2.35 01/28/21 Notable companies reporting before tomorrow's open 01/28/21 Notable companies reporting before tomorrow's open INCY Incyte $78.57 / -1.12 (-1.41%) 02/09/21 Incyte reports Q4 EPS 93c, consensus 75c 02/08/21 Notable companies reporting before tomorrow's open 02/08/21 Notable companies reporting before tomorrow's open 11/05/20 Incyte reports Q3 EPS 23c, consensus 75c LLY LLY Eli Lilly $204.13 / -2.26 (-1.10%) 02/10/21 Eli Lilly won't try to claw back past pay from former CFO Smiley, WSJ reports 12/30/20 Fresenius to administer Lilly, Regeneron COVID antibody drugs, Reuters says 12/23/20 Judge rules against White House drug pricing rule, Reuters says 11/23/20 EU seeks easier access to generic medicines, Reuters says LLY INCY LLY Eli Lilly $204.13 / -2.26 (-1.10%) 02/09/21 Fly Intel: Wall Street's top stories for Tuesday 02/09/21 Fly Intel: Wall Street's top stories at midday 01/29/21 Fly Intel: Wall Street's top stories for Friday 01/29/21 Fly Intel: Wall Street's top stories at midday INCY Incyte $78.57 / -1.12 (-1.41%) 02/09/21 Fly Intel: Pre-market Movers 03/05/21 Healthcare 03/02/21 41st Annual Healthcare Virtual Conference 03/10/21 Global Healthcare Virtual Conference 2021 03/15/21 Eli Lilly - LLY 04/27/21 Eli Lilly - LLY 06/21/21 PDUFA Date for Ruxolitinib Cream 06/22/21 PDUFA Date for Jakafi (ruxolitinib) sNDA for GVHD 07/25/21 PDUFA Date for Retifanlimab LLY INCY LLY Eli Lilly $204.13 / -2.26 (-1.10%) 01/15/21 Eli Lilly call volume above normal and directionally bullish 01/13/21 Early notable gainers among liquid option names on January 13th 01/11/21 Early notable gainers among liquid option names on January 11th 12/09/20 Early notable gainers among liquid option names on December 9th INCY Incyte $78.57 / -1.12 (-1.41%) 01/22/21 Early notable gainers among liquid option names on January 22nd 12/14/20 Early notable gainers among liquid option names on December 14th
Earnings	OneSpaWorld reports Q4 EPS (33c), consensus (21c) » 06:48 03/03/21 03/03 06:48 03/03/21 06:48 OSW OneSpaWorld $11.54 / +0.16 (+1.41%) Reports Q4 revenue $3.8M,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events OSW OneSpaWorld $11.54 / +0.16 (+1.41%) 10/30/20 OneSpaWorld rises after CDC lifts no sail order with conditions 09/16/20 OneSpaWorld CEO sets retirement date, Bonner named CCO OSW OneSpaWorld $11.54 / +0.16 (+1.41%) 01/13/21 Jefferies OneSpaWorld downgraded to Hold at Jefferies following over 50% rally 01/13/21 Jefferies OneSpaWorld downgraded to Hold from Buy at Jefferies 10/30/20 Stifel CDC lifting 'no sail order' a 'clear positive' for cruise liners, says Stifel 06/09/20 Stifel OneSpaWorld price target raised to $10 from $7 at Stifel OSW OneSpaWorld $11.54 / +0.16 (+1.41%) 11/10/20 OneSpaWorld reports Q3 EPS (26c), consensus (25c) 10:00 Today OneSpaWorld - OSW
Downgrade	PNM Resources downgraded to Neutral from Buy at Citi » 06:48 03/03/21 03/03 06:48 03/03/21 06:48 PNM PNM Resources $47.66 / -0.385 (-0.80%) Citi analyst Ryan Levine… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings PNM PNM Resources $47.66 / -0.385 (-0.80%) 02/12/21 PNM Resources investors 'overwhelmingly' approve AVANGRID deal 02/12/21 PNM Resources shareholders approve merger with Avangrid 02/02/21 Avangrid receives clearance from CFIUS for proposed PNM Resources merger 01/27/21 Avangrid says Hart-Scott-Rodino waiting period expired for PNM merger PNM PNM Resources $47.66 / -0.385 (-0.80%) 01/06/21 Wells Fargo PNM Resources downgraded to Underweight from Equal Weight at Wells Fargo 11/18/20 Fly Intel: Top five analyst downgrades 11/18/20 Barclays PNM Resources downgraded to Underweight from Equal Weight at Barclays 10/26/20 UBS PNM Resources downgraded to Neutral from Buy at UBS PNM PNM Resources $47.66 / -0.385 (-0.80%) 12/17/20 PNM Resources sees FY21 ongoing EPS $2.27-$2.37, consensus $2.33 12/17/20 PNM Resources backs FY20 ongoing EPS view $2.23-$2.31, consensus $2.28 10/30/20 PNM Resources backs FY20 ongoing EPS view $2.23-$2.31, consensus $2.24 10/30/20 PNM Resources reports Q3 ongoing EPS $1.40, consensus $1.26

Hot Stocks	Junshi, Coherus BioSciences initiate rolling submission of BLA for toripalimab » 06:48 03/03/21 03/03 06:48 03/03/21 06:48 CHRS Coherus Biosciences $15.69 / -0.38 (-2.36%) Junshi Biosciences and… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings CHRS Coherus Biosciences $15.69 / -0.38 (-2.36%) 02/17/21 Coherus Biosciences announces acceptance of BLA filing for CHS-1420 02/16/21 Coherus CFO Jean-Frederic Viret to resign 02/02/21 Coherus Biosciences to receive $50M strategic investment 02/01/21 Coherus Biosciences, Junshi Biosciences collaborate to co-develop toripalimab CHRS Coherus Biosciences $15.69 / -0.38 (-2.36%) 02/25/21 Citi Coherus Biosciences price target lowered to $27 from $30 at Citi 02/25/21 H.C. Wainwright Coherus Biosciences price target lowered to $29 from $33 at H.C. Wainwright 11/19/20 Mizuho Coherus Biosciences price target lowered to $30 from $35 at Mizuho 08/21/20 Mizuho Express Scripts exclusion does not impact Coherus, says Mizuho CHRS Coherus Biosciences $15.69 / -0.38 (-2.36%) 11/05/20 Coherus Biosciences reports Q3 EPS 47c, consensus 41c
Recommendations	Cinemark price target raised to $30 from $21 at Benchmark » 06:48 03/03/21 03/03 06:48 03/03/21 06:48 CNK Cinemark $23.87 / -0.06 (-0.25%) Benchmark analyst Michael… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options CNK Cinemark $23.87 / -0.06 (-0.25%) 02/22/21 Movie theater operators jump as Gov. Cuomo gives greenlight to NYC reopening 12/22/20 Sony Pictures CEO says 'don't think' will move to 'day and date' film releases 12/03/20 Warner Bros. to release 2021 films in theaters, on HBO Max simultaneously 12/03/20 Warner Bros. to release films in theaters and on HBO Max simultaneously in 2021 CNK Cinemark $23.87 / -0.06 (-0.25%) 02/23/21 Wedbush Cinemark price target raised to $28 from $15 at Wedbush 02/01/21 MKM Partners Cinemark downgraded to Neutral from Buy at MKM Partners 02/01/21 MKM Partners Cinemark downgraded to Neutral from Buy at MKM Partners 01/25/21 Goldman Sachs Cinemark price target raised to $16 from $11 at Goldman Sachs CNK Cinemark $23.87 / -0.06 (-0.25%) 02/26/21 Cinemark reports Q4 EPS ($2.03), consensus ($1.46) 02/25/21 Notable companies reporting before tomorrow's open 02/25/21 Notable companies reporting before tomorrow's open 11/05/20 Cinemark reports Q3 EPS ($1.25), consensus ($1.33) CNK Cinemark $23.87 / -0.06 (-0.25%) 02/22/21 Movie theaters might get OK to reopen in New York City, Deadline says 12/03/20 Cinemark says Warner Bros. hasn't given details on 2021 plan, Bloomberg reports 10/18/20 NY state moves to reopen movie theaters, ski resorts, Bloomberg reports CNK Cinemark $23.87 / -0.06 (-0.25%) 02/26/21 Fly Intel: Pre-market Movers 12/28/20 AMC, Cinemark rise as WW84 scores highest box office opening of pandemic 12/14/20 Fly Intel: Wall Street's top stories for Monday 12/14/20 Cinemark, AMC slip after denying M&A discussions 03/11/21 2021 Consumer, Industrials, & TMT Investor Virtual Conference CNK Cinemark $23.87 / -0.06 (-0.25%) 02/25/21 Cinemark put volume heavy and directionally bearish 02/10/21 Cinemark call volume above normal and directionally bullish 01/19/21 Cinemark put volume heavy and directionally bearish 12/09/20 Cinemark put volume heavy and directionally bearish
Recommendations	Clover Health price target lowered to $13 from $19 at Citi » 06:47 03/03/21 03/03 06:47 03/03/21 06:47 CLOV Clover Health $9.04 / -1.35 (-12.99%) Citi analyst Ralph… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Periodicals On The Fly Options CLOV Clover Health $9.04 / -1.35 (-12.99%) 02/16/21 Greenlight Capital buys FuboTV and Danimer Scientific, exits Intel 02/05/21 Palihapitiya calls Hindenburg's comments on Clover 'spurious' 02/05/21 Clover Health receives letter from SEC on investigation after Hindenburg article 02/05/21 Clover Health says short seller firm's 'rife' with 'sweeping inaccuracies' CLOV Clover Health $9.04 / -1.35 (-12.99%) 02/02/21 Fly Intel: Top five analyst initiations 02/02/21 Citi Clover Health initiated with a Buy at Citi 02/01/21 JPMorgan Clover Health initiated with a Neutral at JPMorgan CLOV Clover Health $9.04 / -1.35 (-12.99%) 02/05/21 Hindenburg, in Clover response, says regular investors shouldn't be last to know CLOV Clover Health $9.04 / -1.35 (-12.99%) 02/05/21 Fly Intel: Wall Street's top stories for Friday 02/05/21 Fly Intel: Wall Street's top stories at midday 02/04/21 Fly Intel: Wall Street's top stories for Thursday 02/04/21 Fly Intel: Wall Street's top stories at midday CLOV Clover Health $9.04 / -1.35 (-12.99%) 03/01/21 Clover Health call volume above normal and directionally bullish 01/25/21 Unusually active option classes on open January 25th 01/13/21 Diagonal spread in Clover Health rolls short January calls out and up 01/08/21 Two new option listings and four option delistings on January 8th
Recommendations	Nutanix estimates raised as several drivers seen, says Susquehanna » 06:46 03/03/21 03/03 06:46 03/03/21 06:46 NTNX Nutanix $29.93 / -0.795 (-2.59%) Susquehanna analyst Mehdi… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options NTNX Nutanix $29.93 / -0.795 (-2.59%) 12/29/20 VMware initiates legal proceedings against former COO for breach of contract 12/09/20 Nutanix appoints Rajiv Ramaswami as CEO 09/08/20 Nutanix rallies after inking new cloud partnership with Microsoft 09/08/20 Nutanix partners with Microsoft Azure for hybrid solution NTNX Nutanix $29.93 / -0.795 (-2.59%) 02/25/21 KeyBanc Nutanix price target raised to $42 from $37 at KeyBanc 02/25/21 Wells Fargo Nutanix price target raised to $40 from $35 at Wells Fargo 02/25/21 Needham Nutanix price target raised to $43 from $37 at Needham 01/13/21 William Blair VMware downgraded to Market Perform at William Blair after executive exits NTNX Nutanix $29.93 / -0.795 (-2.59%) 02/24/21 Nutanix sees Q3 ACV Billings $150M-$155M 02/24/21 Nutanix reports Q2 adjusted EPs (37c), consensus (48c) 02/24/21 Notable companies reporting after market close 11/23/20 Nutanix reports Q1 adjusted EPS (44c), consensus (57c) NTNX Nutanix $29.93 / -0.795 (-2.59%) 02/24/21 Fly Intel: After-Hours Movers 01/13/21 VMware slides as Gelsinger returns to Intel to be new CEO 11/23/20 Fly Intel: After-Hours Movers 09/08/20 Fly Intel: Wall Street's top stories for Tuesday 03/09/21 Nutanix NTNX Nutanix $29.93 / -0.795 (-2.59%) 01/28/21 Nutanix put volume heavy and directionally bearish 01/27/21 Nutanix put volume heavy and directionally bearish 11/23/20 Nutanix options imply 18.4% move in share price post-earnings 11/10/20 Nutanix put volume heavy and directionally bearish
Recommendations	Niu Technologies price target raised to $48 from $37 at Citi » 06:46 03/03/21 03/03 06:46 03/03/21 06:46 NIU Niu Technologies $38.28 / -2.08 (-5.15%) Citi analyst Beatrice Lam… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Events Options NIU Niu Technologies $38.28 / -2.08 (-5.15%) 12/07/20 Aurora Mobile, Niu Technologies enter partnership agreement 10/09/20 Niu Technologies reports Q3 e-scooter sales of 250,889 NIU Niu Technologies $38.28 / -2.08 (-5.15%) 01/15/21 Needham Niu Technologies price target raised to $46 from $36 at Needham 11/06/20 Citi Niu Technologies upgraded to Buy from Neutral at Citi 10/12/20 Piper Sandler Niu Technologies price target raised to $31 from $25 at Piper Sandler 08/17/20 Citi Niu Technologies downgraded to Neutral from Buy at Citi 03/08/21 Niu Technologies - NIU 03/09/21 Niu Technologies NIU Niu Technologies $38.28 / -2.08 (-5.15%) 02/17/21 Niu Technologies call volume above normal and directionally bullish 01/15/21 Niu Technologies put volume heavy and directionally bearish 12/03/20 Largest borrow rate increases among liquid names 11/25/20 Niu Technologies call volume above normal and directionally bullish

General news	FX Action: Broad weakness in the Japanese currency has maintained buoyancy in USD-JPY » 06:45 03/03/21 03/03 06:45 03/03/21 06:45 FX Action: Broad weakness… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial
General news	Week of 2/26 MBA Mortgage Applications to be released at 07:00 06:45 03/03/21 03/03 06:45 03/03/21 06:45
Recommendations	21Vianet price target raised to $47 from $33 at Citi » 06:43 03/03/21 03/03 06:43 03/03/21 06:43 VNET 21Vianet $37.43 / -1.305 (-3.37%) Citi analyst Arthur Lai… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events VNET 21Vianet $37.43 / -1.305 (-3.37%) 11/24/20 21Vianet reports Q3 cabinets under management 51,476 VNET 21Vianet $37.43 / -1.305 (-3.37%) 11/04/20 Daiwa 21Vianet initiated with a Buy at Daiwa 09/28/20 BofA 21Vianet initiated with a Buy at BofA 09/28/20 BofA 21Vianet initiated with a Buy at BofA 07/14/20 UBS 21Vianet initiated with a Buy at UBS VNET 21Vianet $37.43 / -1.305 (-3.37%) 11/24/20 21Vianet reports Q3 EPS 2c, consensus (3c) 26 Aug 05 Mar VNET 21Vianet $37.43 / -1.305 (-3.37%) 01/20/21 Fly Intel: After-Hours Movers 11/25/20 Fly Intel: Pre-market Movers 11/24/20 Fly Intel: After-Hours Movers 03/23/21 21Vianet - VNET
Recommendations	Mayville Engineering results suggest volume recovery continues, says Baird » 06:42 03/03/21 03/03 06:42 03/03/21 06:42 MEC Mayville Engineering $15.15 / +0.44 (+2.99%) Baird analyst Mircea… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events MEC Mayville Engineering $15.15 / +0.44 (+2.99%) 03/02/21 Mayville Engineering not providing financial outlook for 2021 11/02/20 Mayville Engineering is not providing financial outlook MEC Mayville Engineering $15.15 / +0.44 (+2.99%) 02/04/21 Baird Mayville Engineering price target raised to $20 from $14 at Baird 11/04/20 Citi Mayville Engineering price target raised to $13 from $10 at Citi 08/21/20 Fly Intel: Top five analyst upgrades 08/21/20 UBS Mayville Engineering upgraded to Buy from Neutral at UBS MEC Mayville Engineering $15.15 / +0.44 (+2.99%) 03/02/21 Mayville Engineering reports Q4 pro forma EPS 5c, consensus 1c 11/02/20 Mayville Engineering reports Q3 pro forma EPS (5c), consensus (4c) 10:00 Today Mayville Engineering - MEC
Hot Stocks	Stellantis sees 2021 adjusted operating income margin of 5.5%-7.5% 06:42 03/03/21 03/03 06:42 03/03/21 06:42 STLA Stellantis $17.00 / +0.13 (+0.77%) ShowHide Related Items >><< Company News Street Research Periodicals On The Fly Events STLA Stellantis $17.00 / +0.13 (+0.77%) 06:42 Today Stellantis: Fiat Chrysler reports 2020 adjusted net profit EUR1.86B 05:12 Today Stellantis announces $8,010 2020 profit sharing payment to UAW employees 02/17/21 EU passenger car registrations down 24.0% in January 01/27/21 FCA US to pay $30M to resolve investigation involving National Training Center STLA Stellantis $17.00 / +0.13 (+0.77%) 03/02/21 AlphaValue Stellantis upgraded to Buy from Add at AlphaValue 02/24/21 Fly Intel: Top five analyst initiations 02/24/21 Citi Stellantis resumed with a Buy at Citi 02/10/21 Morgan Stanley Renault downgraded to Equal Weight from Overweight at Morgan Stanley STLA Stellantis $17.00 / +0.13 (+0.77%) 02/23/21 Stellantis CEO says car production costs in Italy are higher, Reuters says 02/02/21 'Apple Car' to use E-GMP platform from Hyundai, Apple Insider reports STLA Stellantis $17.00 / +0.13 (+0.77%) 02/02/21 Dell, Palo Alto upgrades among today's top calls on Wall Street 09:30 Today Stellantis - STLA

Recommendations	Citi boosts Micron target to $116, still sees $150 stock longer term » 06:42 03/03/21 03/03 06:42 03/03/21 06:42 MU Micron $91.02 / -3.74 (-3.95%) Citi analyst Christopher… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options MU Micron $91.02 / -3.74 (-3.95%) 02/18/21 Micron's Poppen sells 46,554 common shares 02/16/21 Appaloosa buys Macy's and Kohl's, exits AT&T in Q4 01/26/21 Micron announces volume shipment of 1-alpha node DRAM products 01/14/21 Micron director sells 50K shares of common stock MU Micron $91.02 / -3.74 (-3.95%) 03/02/21 Evercore ISI Micron price target raised to $135 from $105 at Evercore ISI 03/01/21 Wedbush Micron price target raised to $100 from $88 at Wedbush 03/01/21 Barclays Micron price target raised to $110 from $100 at Barclays 02/25/21 Mizuho Micron price target raised to $100 from $85 at Mizuho MU Micron $91.02 / -3.74 (-3.95%) 01/07/21 Micron sees Q2 EPS 75c +/- 7c, consensus 63c 01/07/21 Micron reports Q1 EPS 78c, consensus 71c 01/07/21 Notable companies reporting after market close 12/01/20 Micron raises Q1 adj. EPS view 69c-73c from 40c-54c, consensus 48c MU Micron $91.02 / -3.74 (-3.95%) 02/24/21 Biden to address chip shortages with executive action, WSJ reports 02/11/21 Biden administration called on by chip industry to fund factories, Reuters says 12/04/20 Micron fab power outage may impact global DRAM supply, DigiTimes reports 12/03/20 U.S. in talks with Huawei CFO to settle charges, WSJ reports MU Micron $91.02 / -3.74 (-3.95%) 03/02/21 Zoom Video, TripAdvisor upgrades among today's top calls 02/27/21 Charged: Tesla temporarily halts Model 3 line at CA plant 01/08/21 Fly Intel: Wall Street's top stories for Friday 01/08/21 Fly Intel: Wall Street's top stories at midday 03/31/21 Micron - MU MU Micron $91.02 / -3.74 (-3.95%) 02/26/21 Micron call volume above normal and directionally bullish 01/20/21 Micron call buyer realizes 56% same-day gains 01/07/21 Micron options imply 9.7% move in share price post-earnings 01/05/21 Micron call volume above normal and directionally bullish
Hot Stocks	Stellantis: Fiat Chrysler reports 2020 adjusted net profit EUR1.86B » 06:42 03/03/21 03/03 06:42 03/03/21 06:42 STLA Stellantis $17.00 / +0.13 (+0.77%) Fiat Chrysler reported… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Periodicals On The Fly Events STLA Stellantis $17.00 / +0.13 (+0.77%) 05:12 Today Stellantis announces $8,010 2020 profit sharing payment to UAW employees 02/17/21 EU passenger car registrations down 24.0% in January 01/27/21 FCA US to pay $30M to resolve investigation involving National Training Center STLA Stellantis $17.00 / +0.13 (+0.77%) 03/02/21 AlphaValue Stellantis upgraded to Buy from Add at AlphaValue 02/24/21 Fly Intel: Top five analyst initiations 02/24/21 Citi Stellantis resumed with a Buy at Citi 02/10/21 Morgan Stanley Renault downgraded to Equal Weight from Overweight at Morgan Stanley STLA Stellantis $17.00 / +0.13 (+0.77%) 02/23/21 Stellantis CEO says car production costs in Italy are higher, Reuters says 02/02/21 'Apple Car' to use E-GMP platform from Hyundai, Apple Insider reports STLA Stellantis $17.00 / +0.13 (+0.77%) 02/02/21 Dell, Palo Alto upgrades among today's top calls on Wall Street 09:30 Today Stellantis - STLA
Syndicate	VICI Properties files to sell 60M shares of common stock » 06:41 03/03/21 03/03 06:41 03/03/21 06:41 VICI VICI Properties $28.63 / -0.3 (-1.04%) Morgan Stanley, BofA… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Events VICI VICI Properties $28.63 / -0.3 (-1.04%) 06:38 Today VICI Properties to acquire Venetian Resort's real estate in Las Vegas for $4B 06:34 Today Las Vegas Sands to sell The Venetian, other Las Vegas properties for $6.25B 06:34 Today Apollo Global funds to acquire The Venetian Resort and Sands Expo for $2.25B 12/24/20 VICI Properties enters triple-net lease agreement with EBCI VICI VICI Properties $28.63 / -0.3 (-1.04%) 02/22/21 Deutsche Bank VICI Properties price target raised to $32 from $28 at Deutsche Bank 01/26/21 Goldman Sachs VICI Properties price target raised to $33 from $27 at Goldman Sachs 12/17/20 JPMorgan VICI Properties initiated with an Overweight at JPMorgan 12/16/20 Baird VICI Properties reinstated with an Outperform at Baird VICI VICI Properties $28.63 / -0.3 (-1.04%) 02/18/21 VICI Properties reports Q4 EPS 53c, consensus 48c 02/18/21 VICI Properties sees FY21 AFFO per share $1.82-$1.87, consensus $1.88 02/18/21 VICI Properties reports Q4 AFFO per share 46c, consensus 47c 10/28/20 VICI Properties reports Q3 adjusted FFO 43c, consensus 42c 17 Jun 03/11/21 2021 Consumer, Industrials, & TMT Investor Virtual Conference
Recommendations	B&G Foods price target lowered to $29 from $32 at RBC Capital » 06:41 03/03/21 03/03 06:41 03/03/21 06:41 BGS B&G Foods $30.44 / -0.36 (-1.17%) RBC Capital analyst Nik… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options BGS B&G Foods $30.44 / -0.36 (-1.17%) 02/16/21 Cooperman's Omega Advisors buys GM, exits Lee in Q4 12/23/20 B&G Foods recalls individual containers of Food Club Garlic Powder 12/01/20 B&G Foods sees accretion from acquisition of J. M. Smucker's Crisco oils 11/16/20 B&G Foods CEO Kenneth Romanzi to step aside, David Wenner named interim CEO BGS B&G Foods $30.44 / -0.36 (-1.17%) 01/19/21 Stephens B&G Foods initiated with an Equal Weight at Stephens 01/05/21 Credit Suisse B&G Foods downgraded to Underperform from Neutral at Credit Suisse 07/28/20 Seaport Global B&G Foods initiated with a Neutral at Seaport Global 06/12/20 Fly Intel: Top five analyst initiations BGS B&G Foods $30.44 / -0.36 (-1.17%) 03/02/21 B&G Foods sees FY21 revenue roughly $2.05B-$2.1B, consensus $2.03B 03/02/21 B&G Foods reports Q4 adjusted EPS 35c, consensus 44c 11/16/20 B&G Foods backs FY20 adjusted EPS view $2.30-$2.40, consensus $2.33 11/05/20 B&G Foods sees FY20 adjusted EPS $2.30-$2.40, consensus $2.22 BGS B&G Foods $30.44 / -0.36 (-1.17%) 03/02/21 Fly Intel: After-Hours Movers 10/26/20 Fly Intel: After-Hours Movers 03/04/21 B&G Foods BGS B&G Foods $30.44 / -0.36 (-1.17%) 01/22/21 Largest borrow rate increases among liquid names 12/28/20 Largest borrow rate increases among liquid names 12/08/20 Largest borrow rate increases among liquid names 11/25/20 Largest borrow rate increases among liquid names
Recommendations	Abercrombie & Fitch price target raised to $33 from $28 at Citi » 06:40 03/03/21 03/03 06:40 03/03/21 06:40 ANF Abercrombie & Fitch $27.15 / -0.39 (-1.42%) Citi analyst Paul Lejuez… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options ANF Abercrombie & Fitch $27.15 / -0.39 (-1.42%) 03/02/21 Abercrombie & Fitch plans to resume share repurchase activity 03/01/21 Hollister partners with D'Amelio sisters for mental wellness discussions 02/05/21 Abercrombie & Fitch appoints Ken Robinson to board of directors 01/27/21 Abercrombie & Fitch appoints Holly May as Chief Human Resources Officer ANF Abercrombie & Fitch $27.15 / -0.39 (-1.42%) 06:34 Today RBC Capital Abercrombie & Fitch price target raised to $30 from $27 at RBC Capital 02/16/21 JPMorgan Abercrombie & Fitch price target raised to $27 from $26 at JPMorgan 01/14/21 JPMorgan Abercrombie & Fitch price target raised to $26 from $24 at JPMorgan 12/30/20 B. Riley Securities B. Riley checks show holiday outperformance for four retailers ANF Abercrombie & Fitch $27.15 / -0.39 (-1.42%) 03/02/21 Abercrombie & Fitch reports Q4 adjusted EPS $1.50, consensus $1.22 03/01/21 Notable companies reporting before tomorrow's open 03/01/21 Notable companies reporting before tomorrow's open 01/11/21 Abercrombie & Fitch sees Q4 net sales down 5%-7%, consensus $1.12B ANF Abercrombie & Fitch $27.15 / -0.39 (-1.42%) 03/02/21 Fly Intel: Pre-market Movers ANF Abercrombie & Fitch $27.15 / -0.39 (-1.42%) 11/30/20 Abercrombie & Fitch put volume heavy and directionally bearish

Recommendations	Lamar Advertising price target raised to $88 from $80 at Citi » 06:39 03/03/21 03/03 06:39 03/03/21 06:39 LAMR Lamar Advertising $85.93 / -0.79 (-0.91%) Citi analyst Jason… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research Earnings Events LAMR Lamar Advertising $85.93 / -0.79 (-0.91%) 11/11/20 MKM Partners Lamar Advertising price target raised to $80 from $67 at MKM Partners 11/02/20 Morgan Stanley Lamar Advertising upgraded at Morgan Stanley with recovery not priced in 11/02/20 Morgan Stanley Lamar Advertising upgraded to Overweight from Equal Weight at Morgan Stanley 07/27/20 Wolfe Research Lamar Advertising upgraded to Peer Perform from Underperform at Wolfe Research LAMR Lamar Advertising $85.93 / -0.79 (-0.91%) 02/26/21 Lamar Advertising sees FY21 EPS $2.76-$3.02, consensus $2.94 02/26/21 Lamar Advertising reports Q4 EPS $1.08, consensus 78c 11/05/20 Lamar Advertising raises FY20 AFFO view to $4.65-$4.85 from $4.16-$4.56 11/05/20 Lamar Advertising reports Q3 adjusted FFO $1.32, consensus $1.18 03/25/21 REITwise 2021 Virtual Conference
Hot Stocks	MediciNova to discontinue development of SARS-CoV-2 vaccine for COVID-19 » 06:39 03/03/21 03/03 06:39 03/03/21 06:39 MNOV MediciNova $5.74 / +0.045 (+0.79%) MediciNova announced an… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News On The Fly MNOV MediciNova $5.74 / +0.045 (+0.79%) 01/21/21 MediciNova rises 14% after disclosing activist stake by 3D Investment Partners 12/29/20 MediciNova receives notice of allowance for patent covering MN-166 12/15/20 MediciNova to be added to Nasdaq Biotechnology Index at open on 12/21 11/25/20 MediciNova's MN-166 shows retinal thinning attenuation in Phase 2b trial MNOV MediciNova $5.74 / +0.045 (+0.79%) 01/21/21 Fly Intel: After-Hours Movers 09/23/20 Fly Intel: Pre-market Movers
Recommendations	Manitowoc price target raised to $17 from $15 at Citi » 06:38 03/03/21 03/03 06:38 03/03/21 06:38 MTW Manitowoc $16.37 / -0.485 (-2.88%) Citi analyst Timothy… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events MTW Manitowoc $16.37 / -0.485 (-2.88%) 02/09/21 Manitowoc not giving 2021 guidance due to 'significant' uncertainty 11/05/20 Manitowoc rises 22.5% MTW Manitowoc $16.37 / -0.485 (-2.88%) 02/10/21 Baird Manitowoc price target raised to $17 from $11 at Baird 01/15/21 Barclays Manitowoc price target raised to $17 from $13 at Barclays 10/07/20 Citi Manitowoc price target lowered to $10 from $12 at Citi 08/07/20 Stifel Stifel downgrades Manitowoc on 'abrupt' CEO change, lack of catalysts MTW Manitowoc $16.37 / -0.485 (-2.88%) 02/09/21 Manitowoc reports Q4 adjusted EPS 19c, consensus 9c 11/04/20 Manitowoc sees Q4 revenue $425M-$450M, consensus $360.04M. 11/04/20 Manitowoc reports Q3 adjusted EPS 10c, consensus (29c) MTW Manitowoc $16.37 / -0.485 (-2.88%) 02/09/21 Fly Intel: After-Hours Movers 03/15/21 2021 Industrials Virtual Conference
Recommendations	Inter Parfums price target raised to $75 from $56 at Citi » 06:38 03/03/21 03/03 06:38 03/03/21 06:38 IPAR Inter Parfums $72.03 / -2.65 (-3.55%) Citi analyst Wendy… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly IPAR Inter Parfums $72.03 / -2.65 (-3.55%) 03/01/21 Inter Parfums reinstates 25c per share quarterly dividend 01/11/21 Inter Parfums to acquire EUR 125M office building in Paris for new headquarters IPAR Inter Parfums $72.03 / -2.65 (-3.55%) 01/27/21 BWS Financial Inter Parfums price target raised to $80 from $60 at BWS Financial 01/26/21 DA Davidson Inter Parfums price target raised to $55 from $50 at DA Davidson 12/02/20 DA Davidson Inter Parfums price target lowered to $50 from $55 at DA Davidson 11/11/20 DA Davidson Inter Parfums price target raised to $55 from $39 at DA Davidson IPAR Inter Parfums $72.03 / -2.65 (-3.55%) 03/01/21 Inter Parfums sees FY21 EPS $1.40-$1.45, consensus $1.39 03/01/21 Inter Parfums reports Q4 EPS 47c, consensus 37c 01/25/21 Inter Parfums backs FY21 EPS view $1.20-$1.25, consensus $1.34 01/25/21 Inter Parfums raises FY20 EPS view to $1.15-$1.20 from 80c-84c IPAR Inter Parfums $72.03 / -2.65 (-3.55%) 01/25/21 Fly Intel: After-Hours Movers 12/01/20 Fly Intel: After-Hours Movers
Hot Stocks	VICI Properties to acquire Venetian Resort's real estate in Las Vegas for $4B » 06:38 03/03/21 03/03 06:38 03/03/21 06:38 VICI VICI Properties $28.63 / -0.3 (-1.04%) , LVS Las Vegas Sands $64.94 / +1.895 (+3.01%) , APO Apollo Global $49.89 / -0.42 (-0.83%) VICI Properties (VICI) it… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options VICI LVS APO VICI VICI Properties $28.63 / -0.3 (-1.04%) 06:34 Today Las Vegas Sands to sell The Venetian, other Las Vegas properties for $6.25B 06:34 Today Apollo Global funds to acquire The Venetian Resort and Sands Expo for $2.25B 12/24/20 VICI Properties enters triple-net lease agreement with EBCI 12/24/20 Caesars to sell Caesars Southern Indiana to EBCI for $250M LVS Las Vegas Sands $64.94 / +1.895 (+3.01%) 06:34 Today Las Vegas Sands to sell The Venetian, other Las Vegas properties for $6.25B 06:34 Today Apollo Global funds to acquire The Venetian Resort and Sands Expo for $2.25B 03/01/21 Macau reports February casino revenue up 135.6% to 7.31B patacas 02/25/21 Bill introduced in Florida Senate to authorize sports wagering APO Apollo Global $49.89 / -0.42 (-0.83%) 06:34 Today Las Vegas Sands to sell The Venetian, other Las Vegas properties for $6.25B 06:34 Today Apollo Global funds to acquire The Venetian Resort and Sands Expo for $2.25B 06:31 Today Apollo Global funds to acquire The Venetian Resort and Sands Expo for $2.25B 03/02/21 Apollo Global announces Impact Advisory Committee VICI LVS APO VICI VICI Properties $28.63 / -0.3 (-1.04%) 02/22/21 Deutsche Bank VICI Properties price target raised to $32 from $28 at Deutsche Bank 01/26/21 Goldman Sachs VICI Properties price target raised to $33 from $27 at Goldman Sachs 12/17/20 JPMorgan VICI Properties initiated with an Overweight at JPMorgan 12/16/20 Baird VICI Properties reinstated with an Outperform at Baird LVS Las Vegas Sands $64.94 / +1.895 (+3.01%) 02/09/21 Morgan Stanley Morgan Stanley says legalized sports betting in Texas this year has 'slim' odds 02/08/21 Fly Intel: Top five analyst downgrades 02/08/21 BofA Las Vegas Sands downgraded to Neutral from Buy at BofA 02/08/21 BofA Las Vegas Sands downgraded to Neutral from Buy at BofA APO Apollo Global $49.89 / -0.42 (-0.83%) 01/20/21 Truist Athene Holding price target raised to $55 from $48 at Truist 01/11/21 Wells Fargo Apollo Global price target raised to $55 from $50 at Wells Fargo 12/18/20 Deutsche Bank Apollo Global price target raised to $51 from $49 at Deutsche Bank 11/06/20 Fly Intel: Top five analyst upgrades VICI LVS APO VICI VICI Properties $28.63 / -0.3 (-1.04%) 02/18/21 VICI Properties reports Q4 EPS 53c, consensus 48c 02/18/21 VICI Properties sees FY21 AFFO per share $1.82-$1.87, consensus $1.88 02/18/21 VICI Properties reports Q4 AFFO per share 46c, consensus 47c 10/28/20 VICI Properties reports Q3 adjusted FFO 43c, consensus 42c LVS Las Vegas Sands $64.94 / +1.895 (+3.01%) 01/27/21 Las Vegas Sands reports Q4 adjusted EPS (37c), consensus (32c) 01/27/21 Notable companies reporting after market close 10/21/20 Las Vegas Sands reports Q3 adjusted EPS (67c), consensus (59c) 10/21/20 Notable companies reporting after market close APO Apollo Global $49.89 / -0.42 (-0.83%) 02/03/21 Apollo Global reports Q4 fee related EPS 63c, consensus 50c 02/02/21 Notable companies reporting before tomorrow's open 02/02/21 Notable companies reporting before tomorrow's open 10/29/20 Apollo Global reports Q3 fee-related EPS 63c, consensus 49c 17 Jun LVS APO LVS Las Vegas Sands $64.94 / +1.895 (+3.01%) 02/12/21 Nevada to roll back capacity restrictions on casinos, Reno Gazette Journal says 02/09/21 TX Lt. Gov. sees no support for legalized sports betting, Houston Chronicle says 01/21/21 Japan expects Tokyo Olympics will have to be cancelled, The Times says 01/11/21 NBA postones Pelicans-Mavs, Celtics-Bulls games APO Apollo Global $49.89 / -0.42 (-0.83%) 03/01/21 Michaels attracting buyout interest from private equity players, NY Times says 03/01/21 Apollo, another firm interested in acquiring Michaels, NY Times reports 02/02/21 Apollo remains on UN watch list after Epstein report, FT says 01/20/21 Brookfield, KKR mull offers for $10B Aramco pipeline stake, Bloomberg says LVS APO LVS Las Vegas Sands $64.94 / +1.895 (+3.01%) 03/01/21 Macau GGR spikes over 135% in February vs. last year 02/26/21 Bet On It: Florida and Texas trying to get in on the action 02/19/21 Bet On It: Penn National's lack of promotional spend sets it apart 02/12/21 Bet On It: Texas and Hawaii face opposition to legalized sports betting APO Apollo Global $49.89 / -0.42 (-0.83%) 03/02/21 Fly Intel: Pre-market Movers 02/03/21 Fly Intel: Wall Street's top stories for Wednesday 02/03/21 Fly Intel: Wall Street's top stories at midday 02/03/21 Fly Intel: Pre-market Movers 03/11/21 2021 Consumer, Industrials, & TMT Investor Virtual Conference LVS APO LVS Las Vegas Sands $64.94 / +1.895 (+3.01%) 02/11/21 Las Vegas Sands put volume heavy and directionally bearish 02/05/21 Early notable gainers among liquid option names on February 5th 01/27/21 Las Vegas Sands call volume above normal and directionally bullish 11/02/20 Unusually active option classes on open November 2nd APO Apollo Global $49.89 / -0.42 (-0.83%) 10/22/20 Apollo Global put volume heavy and directionally bearish

Events

Earnings calls, analyst events, roadshows and more

Today at 07:00

MBA Mortgage Applications: Composite Index W/W: 2/26/2021 Government Event
Today at 07:00

MBA Mortgage Applications: Purchase Index W/W: 2/26/2021 Government Event
Today at 07:00

MBA Mortgage Applications: Refinance Index W/W: 2/26/2021 Government Event
OPTN
Today at 08:00

Optinose - OPTN Conference Calls
BQ
Today at 08:00

Boqii - BQ Conference Calls
ISEE
Today at 08:00

Iveric bio - ISEE Conference Calls
TSHA
Today at 08:00

Taysha Gene Therapies - TSHA Conference Calls
Today at 08:15

ADP Employment Report: Private Payrolls M/M: February 2021 Government Event
TAST
Today at 08:30

Carrols Restaurant - TAST Conference Calls
PASG
Today at 08:30

Passage Bio - PASG Conference Calls

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	SWTX X SWTX SpringsWorks Therapeutics Block Trade Managers: Morgan Stanley Priced at: $84.00 1.2M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial VRT X VRT Vertiv Holdings Block Trade Managers: JPMorgan Priced at: $20.70 17.4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial KRTX X KRTX Karuna Therapeutics Secondary Managers: Goldman Sachs & JPMorgan Priced at: $120.00 2.08M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SYNH X SYNH Syneos Health Secondary Managers: Goldman Sachs Priced at: $74.95 7M Shares EAF X EAF GrafTech Spot Secondary Managers: Morgan Stanley Priced at: $11.88 30M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial FRC X FRC First Republic Spot Secondary Managers: BofA, JPMorgan & Morgan Stanley Priced at: $166.50 1.75M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial HLNE X HLNE Hamilton Lane Spot Secondary Managers: JPMorgan Priced at: $88.25 1.45M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial JELD X JELD Jeld-Wen Spot Secondary Managers: Goldman Sachs Priced at: $29.25 8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial RCL X RCL Royal Caribbean Spot Secondary Managers: Morgan Stanley Priced at: $91.00 16.938M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SITC X SITC Site Centers Spot Secondary Managers: Morgan Stanley & Wells Fargo Priced at: $13.20 15M Shares WSC X WSC WillScot Mobile Mini Spot Secondary Managers: Morgan Stanley Priced at: $27.20 12.75M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Tues	OSCR X OSCR Oscar Health IPO Managers: Goldman Sachs, Morgan Stanley & Allen & Co., Wells Fargo, Credit Suisse, BofA, Cowen, LION, Ramirez, SIEB Priced at: $39.00 31M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ASLN X ASLN Aslan Pharmaceuticals Secondary Managers: Jefferies & Piper Sandler Priced at: $4.00 15M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CDLX X CDLX Cardlytics Secondary Managers: BofA, JPMorgan, Wells Fargo & Raymond James Priced at: $130.00 3.85M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial HSKA X HSKA Heska Secondary Managers: JPMorgan & Piper Sandler Priced at: $186.00 941K Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial INDT X INDT Indus Realty Trust Secondary Managers: Morgan Stanley, Citi & Baird, BTIG, JMP Securities, JPMorgan Priced at: $60.00 1.75M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MORF X MORF Morphic Secondary Managers: Jefferies, Cowen, BMO Capital & RBC Capital Priced at: $70.00 3.5M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ICAD X ICAD iCAD Spot Secondary Managers: Guggenheim Priced at: $18.00 1.222M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MGY X MGY Magnolia Oil & Gas Spot Secondary Managers: Credit Suisse & Citi Priced at: $10.50 17M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ORC X ORC Orchid Island Capital Spot Secondary Managers: JPMorgan Priced at: $5.55 8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial RDHL X RDHL RedHill Biopharma Spot Secondary Managers: H.C. Wainwright Priced at: $8.00 4.375M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	No deals
Thurs	No deals
Fri	No deals

Mon	No deals
Tues	GROY X GROY Gold Royalty IPO Managers: H.C. Wainwright & BMO Capital, CIBC, HAYW, Raymond James, Roth Capital, Scotiabank, Sprott, TD Securities $5.00 16M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PLXP X PLXP PLx Pharma Spot Secondary Managers: Raymond James & Oppenheimer $9.14 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SSYS X SSYS Stratasys Spot Secondary Managers: JPMorgan & Stifel $29.00-30.00 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	INNV X INNV InnovAge IPO Managers: JPMorgan, Barclays, Goldman Sachs & Citi, Baird, William Blair, Piper Sandler, Capital One, Loop Capital, SIEB, Roberts & Ryans $17.00-19.00 16.667M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial AMRK X AMRK A-Mark Precious Metals Secondary Managers: DA Davidson & Roth Capital, CIBC $27.97 2.5M Shares COHU X COHU Cohu Secondary Managers: Citi, Goldman Sachs & Stifel, B. Riley Securities, Craig-Hallum, DA Davidson $45.99 4.5M Shares DGII X DGII Digi International Secondary Managers: Piper Sandler $23.46 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial FVRR X FVRR Fiverr Secondary Managers: JPMorgan, Goldman Sachs, Morgan Stanley $279.44 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SLQT X SLQT SelectQuote Secondary Managers: Credit Suisse, Morgan Stanley, Goldman Sachs, RBC Capital, Barclays, Citi, Evercore ISI & Jefferies, Cantor Fitzgerald, Keefe Bruyette, Piper Sandler, Drexel Hamilton $32.22 10.6M Shares
Thurs	NRIX X NRIX Nurix Therapeutics Secondary Managers: JPMorgan, Piper Sandler & Stifel, RBC Capital, Needham $35.91 4M Shares
Fri	No deals

View All Syndicate Announcements »

Agnico Eagle price target raised to C$60 from C$54 at BMO Capital

TODAY'S FREE FLY STORIES

Get Full Fly Access